The treatment of chronic heart failure in general practice and the role of ibopamine (Inopamil®)

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Evidence for the role and importance of neuroendocrine modulation apart from pre- and afterload reduction as hemodynamic properties in the treatment of chronic heart failure (HF) is accumulating. The mainstay of therapy today are diuretics, digoxin and vasodilators, probably preferably converting enzyme inhibitors (CEI). Apart from vasodilating effects, CEI possess favorable neuroendocrine modulating properties. The recent development of the oral dopamine agonist ibopamine increases the possibilities for the treatment of HF. Ibopamine induces vasodilation and favorably influences the neuroendocrine system, with mild beneficial renal effects in patients with HF by different mechanisms compared to other drugs. Several clinical studies have demonstrated the efficacy and safety of ibopamine in the treatment of HF.

Translated title of the contributionThe treatment of chronic heart failure in general practice and the role of ibopamine (Inopamil®)
Original languageDutch
Pages (from-to)169-174
Number of pages6
JournalTGO - Tijdschrift voor Therapie Geneesmiddel en Onderzoek
Volume18
Issue number6
Publication statusPublished - 1 Jan 1993

Cite this

@article{b53097e8cdcd4f448cb13e21391b9e28,
title = "DE BEHANDELING VAN CHRONISCH HARTFALEN IN DE HUISARTSENPRAKTIJK EN DE ROL VAN IBOPAMINE (INOPAMIL{\circledR})",
abstract = "Evidence for the role and importance of neuroendocrine modulation apart from pre- and afterload reduction as hemodynamic properties in the treatment of chronic heart failure (HF) is accumulating. The mainstay of therapy today are diuretics, digoxin and vasodilators, probably preferably converting enzyme inhibitors (CEI). Apart from vasodilating effects, CEI possess favorable neuroendocrine modulating properties. The recent development of the oral dopamine agonist ibopamine increases the possibilities for the treatment of HF. Ibopamine induces vasodilation and favorably influences the neuroendocrine system, with mild beneficial renal effects in patients with HF by different mechanisms compared to other drugs. Several clinical studies have demonstrated the efficacy and safety of ibopamine in the treatment of HF.",
author = "Girbes, {A. R.J.}",
year = "1993",
month = "1",
day = "1",
language = "Dutch",
volume = "18",
pages = "169--174",
journal = "TGO - Tijdschrift voor Therapie Geneesmiddel en Onderzoek",
issn = "0921-562X",
number = "6",

}

DE BEHANDELING VAN CHRONISCH HARTFALEN IN DE HUISARTSENPRAKTIJK EN DE ROL VAN IBOPAMINE (INOPAMIL®). / Girbes, A. R.J.

In: TGO - Tijdschrift voor Therapie Geneesmiddel en Onderzoek, Vol. 18, No. 6, 01.01.1993, p. 169-174.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - DE BEHANDELING VAN CHRONISCH HARTFALEN IN DE HUISARTSENPRAKTIJK EN DE ROL VAN IBOPAMINE (INOPAMIL®)

AU - Girbes, A. R.J.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Evidence for the role and importance of neuroendocrine modulation apart from pre- and afterload reduction as hemodynamic properties in the treatment of chronic heart failure (HF) is accumulating. The mainstay of therapy today are diuretics, digoxin and vasodilators, probably preferably converting enzyme inhibitors (CEI). Apart from vasodilating effects, CEI possess favorable neuroendocrine modulating properties. The recent development of the oral dopamine agonist ibopamine increases the possibilities for the treatment of HF. Ibopamine induces vasodilation and favorably influences the neuroendocrine system, with mild beneficial renal effects in patients with HF by different mechanisms compared to other drugs. Several clinical studies have demonstrated the efficacy and safety of ibopamine in the treatment of HF.

AB - Evidence for the role and importance of neuroendocrine modulation apart from pre- and afterload reduction as hemodynamic properties in the treatment of chronic heart failure (HF) is accumulating. The mainstay of therapy today are diuretics, digoxin and vasodilators, probably preferably converting enzyme inhibitors (CEI). Apart from vasodilating effects, CEI possess favorable neuroendocrine modulating properties. The recent development of the oral dopamine agonist ibopamine increases the possibilities for the treatment of HF. Ibopamine induces vasodilation and favorably influences the neuroendocrine system, with mild beneficial renal effects in patients with HF by different mechanisms compared to other drugs. Several clinical studies have demonstrated the efficacy and safety of ibopamine in the treatment of HF.

UR - http://www.scopus.com/inward/record.url?scp=0027179143&partnerID=8YFLogxK

M3 - Review article

VL - 18

SP - 169

EP - 174

JO - TGO - Tijdschrift voor Therapie Geneesmiddel en Onderzoek

JF - TGO - Tijdschrift voor Therapie Geneesmiddel en Onderzoek

SN - 0921-562X

IS - 6

ER -